Although many specific IGF2BP1 small molecule inhibitors have been recently identified in solid cancers, few were applied to hematological malignancies (Shang et al. 2023; Singh et al. 2024; Wallis et al. 2022). This evidence concerns the gene IGF2BP1 and hematologic disorder.